Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 1/20 | 0.52 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14275292 | 0.89 | GAA (0.54) | BCL9CTNNB1KMT2AMAPTGAA | |
| SCHEMBL14275297 | 0.89 | GAA (0.54) | BCL9CTNNB1KMT2AMAPTGAA | |
| SCHEMBL27818621 | 0.86 | MGLL (0.52) | BCL9CTNNB1KMT2AMAPTGAA | |
| SCHEMBL7050818 | 0.85 | BCL9 (0.46) | BCL9CTNNB1KMT2AMAPTGAA | |
| SCHEMBL7050819 | 0.85 | BCL9 (0.46) | BCL9CTNNB1KMT2AMAPTGAA | |
| SCHEMBL7761879 | 0.83 | GAA (0.49) | BCL9CTNNB1KMT2AMAPTGAA | |
| SCHEMBL7328515 | 0.82 | TDP1 (0.50) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL7338569 | 0.82 | TDP1 (0.50) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL7050815 | 0.82 | BCL9 (0.57) | BCL9CTNNB1KMT2AMAPTGAA | |
| SCHEMBL18966687 | 0.81 | MAPT (0.48) | BCL9CTNNB1KMT2AMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113387909-B | Medical application of 2, 3-epoxysuccinyl derivative | 中国人民解放军军事科学院军事医学研究院 | 2023-11-14 | — | — | CN | disclosed |
| EP-3424913-B1 | 2,3-EPOXY SUCCINYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND USES THEREOF | INST PHARMACOLOGY & TOXICOLOGY ACADEMY MILITARY MEDICAL SCIENCES PLA CHINA (CN) | 2023-04-05 | — | — | EP | disclosed |
| US-10647690-B2 | 2,3-epoxy succinyl derivative, preparation method and use thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2020-05-12 | — | — | US | disclosed |
| US-20170166543-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIZING (2S,3S)-TRANS-EPOXYSUCCINYL-L-LEUCYL-AMIDO-3-METHYLBUTANE ETHYL ESTER | AMERICAN LIFE SCIENCE PHARMACEUTICALS INC (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170166543-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIZING (2S,3S)-TRANS-EPOXYSUCCINYL-L-LEUCYL-AMIDO-3-METHYLBUTANE ETHYL ESTER | AMERICAN LIFE SCIENCE PHARMACEUTICALS INC (US) | 2017-06-15 | — | — | US | disclosed |
| WO-2015117094-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIZING (2S,3S)-TRANS-EPOXYSUCCINYL-L-LEUCYL-AMIDO-3-METHYLBUTANE ETHYL ESTER | AMERICAN LIFE SCIENCE PHARMACEUTICALS, INC. (US) | 2015-08-06 | — | — | WO | disclosed |
| EP-0921122-B1 | EPOXYSUCCINAMIDE DERIVATIVES OR SALTS THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2003-05-21 | — | — | EP | disclosed |
| US-6551999-B1 | For therapy and prophylaxis of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, metastasis of tumors | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2003-04-22 | — | — | US | disclosed |
| EP-0771565-B1 | Angiogenesis inhibitor | SENJU PHARMA CO (JP) | 2003-01-02 | — | — | EP | disclosed |
| EP-0808839-B1 | EPOXYSUCCINAMIDE DERIVATIVES OR SALTS THEREOF, AND DRUGS CONTAINING THE SAME | TAIHO PHARMACEUTICAL CO LTD (JP) | 2001-05-23 | — | — | EP | disclosed |
| EP-0928786-A1 | Angiogenesis inhibitor | Senju Pharmaceutical Co., Ltd. (JP) | 1999-07-14 | — | — | EP | disclosed |
| EP-0927716-A1 | Angiogenesis inhibitor | Senju Pharmaceutical Co., Ltd. (JP) | 1999-07-07 | — | — | EP | disclosed |
| EP-0921122-A1 | NOVEL EPOXYSUCCINAMIDE DERIVATIVES OR SALTS THEREOF | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 1999-06-09 | — | — | EP | disclosed |
| US-5883121-A | INHIBITING ACTIVITY AGAINST CATHEPSIN, AND IS USEFUL FOR PREVENTION AND TREATMENT OF OSTEOPATHY SUCH AS OSTEOPOROSIS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1999-03-16 | — | — | US | disclosed |
| EP-0838460-A1 | PIPERAZINE DERIVATIVES AND USE OF THE SAME | Senju Pharmaceutical Co., Ltd. (JP) | 1998-04-29 | — | — | EP | disclosed |
| EP-0808839-A1 | EPOXYSUCCINAMIDE DERIVATIVES OR SALTS THEREOF, AND DRUGS CONTAINING THE SAME | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1997-11-26 | — | — | EP | disclosed |
| EP-0771565-A2 | Angiogenesis inhibitor | Senju Pharmaceutical Co., Ltd. (JP) | 1997-05-07 | — | — | EP | disclosed |
| EP-0407017-B1 | Epoxysuccinic acid derivatives useful as specific inhibitors of cathepsin B | TAISHO PHARMACEUTICAL CO LTD (JP) | 1995-05-17 | — | — | EP | disclosed |
| US-5068354-A | Cathepsin B inhibitors, enzyme inhibitors for muscular disorders | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1991-11-26 | — | — | US | disclosed |
| EP-0407017-A1 | Epoxysuccinic acid derivatives useful as specific inhibitors of cathepsin B | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1991-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166543-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIZING (2S,3S)-TRANS-EPOXYSUCCINYL-L-LEUCYL-AMIDO-3-METHYLBUTANE ETHYL ESTER | PTMS, LTA, LPXN | BCL9 3812/4885CTNNB1 3503/4885KMT2A 1979/4885 |
| US-10647690-B2 | 2,3-epoxy succinyl derivative, preparation method and use thereof | CTSB, CTSV, CTSS | BCL9 1492/4885CTNNB1 2731/4885KMT2A 3708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.